<div id="readability-page-1"><p>TD Cowen analyst Marc Frahm has maintained their bullish  stance on <span>BDTX</span> stock, giving a Buy rating on April 29.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Marc Frahm has given his Buy rating due to a combination of factors tied to Black Diamond Therapeutics’ lead asset and financial position. He highlights silevertinib (BDTX-1535) as a differentiated, CNS-penetrant EGFR inhibitor with broad activity across non-classical EGFR-mutant NSCLC, including strong responses in brain metastases, and sees upcoming ASCO DOR/PFS data as a key catalyst that could reinforce its competitiveness despite prior concerns about dose reductions and rival therapies.</p> <p>He also notes that the company’s cash balance of roughly $118 million provides runway into the second half of 2028, supporting both regulatory interactions and clinical execution. In parallel, the initiation of a randomized Phase 2 trial in EGFR-mutant GBM, with PFS data expected in the first half of 2028, offers an additional value driver, and potential partnership structures for a pivotal NSCLC program could preserve long-term upside, collectively justifying a continued Buy stance.</p> <p>In another report released on April 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.</p></div>

BDTX

LABU

SBIO

<p>TD Cowen analyst Marc Frahm has reiterated a Buy rating on Black Diamond Therapeutics (BDTX) stock, citing its differentiated EGFR inhibitor, silevertinib (BDTX-1535), and a strong cash position of approximately $118 million, which supports operations through 2028. He anticipates that upcoming ASCO data will enhance the drug's competitiveness. Additionally, a Phase 2 trial in EGFR-mutant GBM is set to provide further value, while potential partnerships for NSCLC could offer long-term benefits. H.C. Wainwright also maintains a Buy rating with an $11.00 price target.</p>

- Analyst Marc Frahm from TD Cowen maintains a bullish outlook on BDTX stock, issuing a buy rating on April 29.  
- He emphasizes the potential of silevertinib (BDTX-1535) as a differentiated EGFR inhibitor with notable activity in non-small cell lung cancer, citing upcoming ASCO DOR/PFS data as a key catalyst.  
- Furthermore, he notes the company's substantial cash reserve and ongoing clinical trials as supporting factors for the buy recommendation, which is echoed by H.C. Wainwright with a target price of $11.00.

Tip Ranks

Black Diamond Therapeutics

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Analyst Reiterates Buy on Black Diamond Therapeutics, Citing Differentiated EGFR Inhibitor and Strong Cash Runway Through 2028